Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The bashers of IPIX are neither buyers or sellers, for some reason they want the company destroyed and have worked toward that goal for years. The lack of volume speaks for its self.
I don't have private messaging but do believe Beamed will be working on both cancer and epilepsy.
Hi Mack G, Frenchbroad and all true investors.
I decided to check in again after a long absense, little change except It isn't a case of the Fox is in the hen house anymore, The fox has taken over the hen house and has been joined by the pack.Guess one would say its the fox den.
They aren't letting her win in Arizona, she is fighting like HELL to claim the election she won and a VP for Trump isn't the problem today Losing our Country is the problem today, Joe Biden is openly commiting TREASON right in the open, There is a movement afoot to stop him, Jovon, Dave and others are working hard to help. .
Ever hear of the Brunson case?
The second person is DAVE JOSE, his knowledge of Constutional Law is amazing and the things he is involved in will be eye opening for those who take the time to get acquainted allso works with Jovon Pulitzer: https://rumble.com/user/Davecaresforyou
I would like to Introduce a couple of prople who have made a difference, first is JOVON HUTTON PULITZER, he did the Forensic audit in Az. and is working on several other states with voter problems. He is very active and a true Patriot: Has a lot of pod cast available. This link is an analysis of the Az trial that finished yesterday.BE SURE AND LISTEN TO THE NATIONAL ANTHEM IN THIS LINK.
https://jovanhuttonpulitzer.locals.com/upost/3250977/7-am-cst-live-melee-over-maricopa-lets-review-kari-lake-trial-reviewing-closing-comments
WE did it at Schwab, only took a few days. If you have a local Schwab office contact them.
There will be a huge demand for the BMed, Sting Ray Laser system, it will do for the intricate treatment of brain Cancer and epilepsy and will become even more successful than the da vinci robotic surgery system. and millions of people around the world who are affected will be able to get treatment.
First bought in 2008.
It will, and should be used, in all of the above. I know if I have access to the nasal spray I would use it, based on past experiences with other products that work against Covid. I might even try it in a nebulizer.
Like "B" the options for using the technology will be almost unlimited.
INNOVATION PHARMACEUTICAL, NEWS!!!!
NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy “Game-Changing Breakthrough”
Innovation Pharmaceuticals believes U.K. launch of MRgLITT for refractory focal epilepsy substantiates its investment in advanced laser technology of BT BeaMedical
WAKEFIELD, MA / October 26, 2022 Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide shareholders insight on a substantial industry development that is relevant to Innovation Pharmaceuticals’ investment in BT BeaMedical Technologies Ltd. (“BeaMed”).
On Saturday, October 22, 2022, the United Kingdom’s National Health System (NHS) announced the launch of a program to provide MR-guided laser interstitial thermal therapy (MRgLITT) for children and adults with refractory focal epilepsy who haven’t responded to conventional drugs. The first surgeries are scheduled to take place early in 2023. The implications for introducing laser therapy for epilepsy were summed up by the NHS Medical Director for Specialised Services, characterizing the technology as a “game-changing breakthrough.”
Conventional neurosurgery for epilepsy is limited and invasive, translating to thousands of patients not qualifying for or electing the treatment, which involves a craniotomy and excision of the part of the brain causing seizures. Often, the problematic area is inaccessible, eliminating neurosurgery as a viable treatment option. For those able to undergo surgery, typical recovery includes a week in the hospital and three months of recovery at home, a period characterized by pain management and infection risk.
Fiber optic laser therapy offers a monumental improvement in epilepsy care. This requires making a hole approximately 1.5 millimeters (about the width of a grain of rice) in the skull, allowing clinicians to better target areas of the brain, reduce risks, and shrink recovery times for patients, typically down to less than a week.
BeaMed’s novel laser technology is similar in concept to the one being advanced in the U.K., but contains additional features designed to enhance, in real-time, control of energy distribution over an extended time to optimally treat epileptic focal points. Differentiation in BeaMed’s technology revolves around shaping of the energy such that it can treat the lesions better in terms of directionality and matching of the energy to the area while avoiding non-targeted structures, which can be critical in many cases up to the point of avoiding treatment because of the possible danger to nearby brain tissue.
If approved for epilepsy, BeaMed technology likely would increase the number of candidate patients since it is able to target larger areas of the brain. Increased volume of treatment in epilepsy has also been associated with improved outcomes.
The Company believes that the NHS news further substantiates its investment in BeaMed and the importance of novel laser therapy approaches, which we expect to become the next standard of care for epilepsy. BeaMed is at the forefront of the industry with its next-generation laser system that it hopes one day can be a safe and effective treatment option for the 70 million people worldwide suffering from the disease.
More information on BeaMed can be found on its company website and via a presentation by BeaMed management introducing the company, at the links below.
BeaMed company website:
www.beam-med.com
BeaMed management introduction to company:
www.youtube.com/channel/UCyoklsj7NfFMpPzC81sXzHg
WHY???EXCLUSIVE: Top NIH director admits Boston lab that created new Covid strain did NOT clear research with agency... and only learned of details on DailyMail.com
https://www.dailymail.co.uk/health/article-11327741/Top-NIH-director-admits-Boston-lab-created-new-Covid-strain-did-NOT-clear-research-agency.html?ito=push-notification&ci=z0gcN2yR6E&cri=inNfuO7ZR8&si=28067494&xi=0944a12c-0e89-4f08-900c-c33469a8e664&ai=11327741
Other alternatives to Vaccines works to.
petermantx, I could invision Brilacidin licensing with one of the BP'S or more. The ABSSSI trials were done without the Government. All we need is one break be it the Nasal mist or a partnership and we will be off to the races, I have no doubt Leo, is on it, and working very hard to "make it happen".. .
Yeah, I decided to add this week, another 300.........LOL
Sure wish some of the oldtimers would come back, would like to hear their take on the progress we have made The Dane, Just the Facts mam and others. At least have them check in to know their still with us.
The story is just beginning! The share price in no way reflects the value of our pipeline, as many will realize before long, when they pull their head out of their.............. the sand.
I suggest that your LOL, is missplaced or that Leo Ehrlic, president and CEO of Innovation Pharmaceuticals Inc. has done a super human job directing and managing our Company. Perhaps you may not be aware of all the vitro, and vivo, testing, Leo has been able to acquire for I P at no cost to us.
Someone had to make those contacts, someone had to convince the DoD, NIH, NIAID that we had something worth considering.Leo is responsible for all of that.alone? How many millions of dollars would we have had to put up to have accomplished that.
When we measure Leo's accomplishments against money spent and the results, anyone would have to recognize Leo as a super leader for our company and recognize Leo for those accomplishments.
Leo accomplished all of those thisgs while fighting off attacks by MAKO and the vultures who have been attempting to destroy Leo's credibility for the past several years. LOL
CEO Leo Ehrlich, Innovation Pharmaceuticals, Inc. and Staff, very busy following the progress of Brilacidin working for shareholders interest.
"BRI converts CAS into a fungicidal drug and overcomes CAS-resistance
We decided to concentrate our further analysis on the host defense peptide mimetic brilacidin (BRI) since this drug candidate has undergone several clinical trials showing therapeutic benefit. BRI MIC for A. fumigatus is 80 µM (Table 1) and the A. fumigatus conidial viability was tested after 48 h of exposure to a combination of CAS 0.2 or 0.5 µg/ml combined with 20 µM BRI (Figure 2A). The combination of 0.2 or 0.5 µg/ml of CAS with 20 µM BRI reduced A. fumigatus conidial viability by 85% and 100%, respectively (Figure 2A). BRI 20 µM could also synergize with subinhibitory VOR concentrations of 0.125 and 0.25 µg/ml by reducing the A. fumigatus conidial viability by 92% and 99%, respectively (Figure 2A)."
Figure 2
BRI enhances the activity of POSA against Mucorales fungi
POSA is used for treating patients with lethal mucormycosis as a step-down therapy to liposomal amphotericin B (LAMB) or in lieu of LAMB in patients who are refractory or intolerate to the latter drug (Cornely et al. 2019). We investigated if BRI could potentiate the activity of POSA against the most common causes of mucormycosis including Rhizopus delemar, R. oryzae, Lichtheimia corymbifera, Mucor circineloides. The growth of these fungi was measured in a checkerboard 96-well assay for which BRI concentrations of 64-0.12 µg/mL and POSA concentrations of 16-0.25 µg/mL were used. In two independent experiments, the Fractional Inhibitory Concentrations (FIC) indices for these two drugs ranged between 0.51-1.12 indicating additive effect for BRI when added to POSA against the tested Mucorales fungi (Table 3). Thus, unlike VOR and BRI against A. fumigatus, it appears that BRI can potentiate the activity of POSA against Mucorales fungi in vitro.
View inlineView popup
Table 3.
https://www.biorxiv.org/content/10.1101/2022.09.28.509882v2.full
Gilead will have an order that will probably cover all of their costs of development and profit, upon signing as a partner, the DOD will need a few million doses for use and stockpiling,, a total win for Gilead again, more billions puuring into their coffers plus we will have some revenue coming our way.
The vultures have robbed us shareholders of billions of dollars. Had the attack by MAKO not have happened, Leo, could have easily raised enough money, with stock sales from the treasury to have run the third phase trial, for ABSSSSI, and a possible phase 2 for Kevitrin. At the time the attacks begin we had around 120 million shares outstanding, with 170 million held in the treasury,
Even with ther failure of the Pruisol phase 2 B, we would have had other phases going to offset the disasterous results. but with the MAKO vultures and trial failure it totally took our legs from underneath us.
Hopefully the vultures will go away when the successful results of the indicastions begin to evolve. NAH, there will always be the vultures waiting for a stolen meal, spreading their FUD to make weak investors sell their shares, so the vultures can make a few pennies..
Leo has done everything in his power to keep IPIX alive but even now we have the back biting haters who won't stop their attacks even though we have several stages of success with Brilacidin. Kevetrin is a casulty of the vultures, and represented my original motivation for investing, in CTIX.
Yep! We could have been worth much more than $20.00 per share except for the vultures.
Better re read my post, I didn't say anything about Leo releasing a pr to tell share holders to sell. .
"Blue Fin So, Leo is going to issue a PR telling share holders to sell .??
That statement is as ridiculous as your 20.00 share price.".
My intent! I intend to continue to add shares at these prices until "HELL FREEZES OVER", or until LEO says sell which I sincerly expect to happen..........soon
Remember the judge protected the bandits when Leo attempted to file for sanctions:
OPINION AND ORDER re: 62 MOTION for Attorney Fees PURSUANT TO THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995, filed by Cellceutix Corporation, Leo Ehrlich, Krishna Menon. For the reasons stated in this Opinion, Defendants' motion for sanctions is DENIED. The Clerk of Court is directed to terminate the motion pending at docket entry 62. (Signed by Judge Katherine Polk Failla on 3/29/2017) (cla) (Entered: 03/29/2017)
ia601609.us.archive.org/26/items/gov.uscourts.nysd.447344/gov.uscourts.nysd.447344.docket.html
IPIX share price undervalued: If it wasn't for Mako and the vultures who work for them our share price could be as much as $20.00 per share. Not to worry, we have a pipeline that appears to be endless in new indications and one of the BP's will pay Leo's price, sooner or later, with Brilacidin doubling the effectivness of Merck's drug I have no doubts anymore. LEO, WILL COME THROUGH, INVESTORS WILL HAVE THE LAST LAUGH.
Almost forgot about,Gilead's Remdesivir, / Brilacidin and covid. nah Gilead or Merck, wouldn't be interested, in Brilacidin, right?
Attacks continue in Attempt to destroy IPIX and Shareholders:
Mako clearly states that it shorts Cellceutix stock. Seeking Alpha, an investor website, has a policy on its website that it allows some of its contributing authors to use pseudonyms, but the publisher itself requires the authors’ full names. They must also reveal any stock positions they write about.
https://www.biospace.com/article/anonymous-short-trader-attacks-cellceutix-again-/
With the clinical, / trial Data, POC, there should be licensing and partnerships being announced ..............soon.
"Pivotal clinical trials for antifungal drugs are generally smaller than those in other infectious disease areas, requiring between 300 and 600 patients. Caspofungin sales were estimated to be $414 million in 2021, with the global antifungal drugs market estimated at $14.8 billion in 2021 and expected to reach $20.5 billion by 2030."
NEWS! October 4, 2022
Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin
Brilacidin
· In pre-clinical studies, Brilacidin shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited potent stand-alone efficacy against Cryptococcus neoformans
· These data suggest Brilacidin has potential as a novel antifungal agent
WAKEFIELD, MA / October 4, 2022 Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced publication of a scientific article on the antifungal activity of Brilacidin, the Company’s defensin-mimetic drug candidate with antimicrobial and immunomodulatory properties. The paper, accessible at the link below as a preprint and to be submitted for peer review, is based on independent research conducted primarily by scientists at the University of São Paulo, Brazil. A corresponding patent application related to this work has been filed.
· Fernanda dos Reis T, Alves de Castro P, Bastos R, Pinzan CF, Souza PFN, Ackloo S, Hossain MA, Drewry D, Alkhazraji S, Ibrahim A, Hyunil J, DeGrado WF. “A Host Defense Peptide Mimetic, Brilacidin, Potentiates Caspofungin Antifungal Activity Against Human Pathogenic Fungi.”
bioRxiv 2022.09.28.509882; doi.org/10.1101/2022.09.28.509882
Summary of Brilacidin Antifungal Research Findings
Following an in vitro drug screening of 1,402 compounds, Brilacidin showed promising antifungal activity and was subsequently selected for additional pre-clinical evaluation, including in combination with caspofungin (CAS), voriconazole (VOR), and posaconazole (POSA), all current antifungal treatments.
In cell culture, in Aspergillus fumigatus (A. fumigatus), Brilacidin converted CAS from a fungistatic into a fungicidal drug, enabling it to overcome both drug resistance and biofilm formation. Brilacidin exerted, to a lesser degree, synergistic effects with VOR in A. fumigatus. Further in vitro testing showed Brilacidin synergized with CAS in C. albicans, C. auris and C. neoformans. In an A. fumigatus immunosuppressed mouse model in invasive pulmonary aspergillosis, Brilacidin plus CAS cleared infection in the lungs by almost 95 percent, compared to ~50 percent when each compound was administered individually. Brilacidin also showed in vitro an additive inhibitory effect when combined with POSA in several species of Mucorales, the main etiological agents of mucormycosis, commonly referred to as black fungus. Mortality rates can be as high as 90 percent in this fungal disease.
Interestingly, Brilacidin showed potent in vitro stand-alone efficacy (MIC=2.5µM) in C. neoformans, a major driver of illness in people living with HIV/AIDS. C. neoformans, for which few effective treatments are available, causes an estimated 220,000 cases of cryptococcal meningitis worldwide each year and is associated with an 80 percent mortality rate.
A proposed antifungal mechanism of action of Brilacidin involves membrane depolarization by impacting calcineurin and cell wall integrity, as informed by protein kinase inhibitory experiments and genetic screenings of protein phosphatase null mutants.
“It is a remarkable feature of Brilacidin that it can potentiate multiple antifungals, in different pathogenic fungi, including hard-to-treat species. New antifungal combination strategies are urgently needed due to a scarcity of novel agents, alongside emerging resistance in the clinical setting,” commented Gustavo Henrique Goldman, Professor of Molecular Biology, University of São Paulo, Brazil, and a Chief Editor for Frontiers in Fungal Biology, a peer-reviewed journal dedicated to the study of mycology. “Another notable finding from our research is that Brilacidin shows exceptional potency of its own as a monotherapy against C. neoformans, a particularly problematic fungus. We look forward to broadening our planned studies of Brilacidin’s antifungal properties.”
About Antifungal Diseases 1, 2, 3
There are up to 5 million fungal species populating the earth, of which approximately 100,000 species have been identified. About 300 fungal species cause disease in humans. Overall, Candida, Cryptococcus and Aspergillus represent the main causative organisms of invasive fungal infections. There is a large unmet medical need for developing novel antifungal agents, particularly given the emergence of resistance in the clinical setting. The utility of current antifungal treatments is limited due to toxicity, fungistatic and not fungicidal properties, as well as drug interaction concerns. In the United States, antifungal drugs can qualify for expedited clinical development, under Qualified Infectious Disease Product designation, Orphan Drug designation, and the limited population pathway development program. Pivotal clinical trials for antifungal drugs are generally smaller than those in other infectious disease areas, requiring between 300 and 600 patients. Caspofungin sales were estimated to be $414 million in 2021, with the global antifungal drugs market estimated at $14.8 billion in 2021 and expected to reach $20.5 billion by 2030.
1 Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy
2 Global Caspofungin Market Research Report 2022 (Status and Outlook)
3 Antifungal Drugs Market Size to be worth $20.5 Billion by 2030: Grand View Research,
I managed to Buy 500K for offset trade, If I sell it before Jan 1 I get a huge tax write of, if it goes up I get cap gains less loss on the profit, win, win. Just a thought. Transfered my old IRA account into a Roth.
COVID and the militasry, why the DOD may be worried:
"At least one study released in June that has yet to be peer-reviewed seems to support that theory. Researchers analyzed more than 5.6 million US veterans’ health records and found that repeat COVID infections (with a mixture of the Delta and Omicron variants) may have a cumulative effect, each positive test bringing greater risks of serious health consequences such as heart, kidney, gastrointestinal, and neurological disorders."
https://www.buzzfeednews.com/article/katiecamero/covid-reinfection
When the Indications begin emerging, we will al be rewarded for our patence, would love to hear from dp70 with some of her insight from the galaxy.
FB your contributions adds great value to the board Thanks!
CMC, Thank you very much, you bring hope and truth that we can rely on.
With all of the data from the human trials, we may get some surprising news, very soon, concerning Brilacidin as a nasal spray,.I think Leo may have this in the can ready for the preimer of the Brilacidin grand debut.
Just think of the number of lives that could have been saved with a nasal spray that kills the virus on contact.
As usual you make some great points. However with the OM trials completed, the effacy of Brilacidin a grand slam all of the applications showing Brilacidin to be safe and effective against over 20 virus strains I believe they are way ahead of us and probably already have the nasal spray formula in focus. With the data from the swish and spit,, over 500 IV injections, UC enema's is any indication the Nasal spray / inhalent, should be a cake walk.
"Ongoing efforts are focused on dosing strategies for brilacidin to improve in vivo effectiveness in the
form of a nasally-delivered countermeasure"
What a super Prophalactic,Brilacidin would be,any virus anytme. A non toxic inhalent that kills a virus on contact.ITS COMING!!!
I am more drawn to the confirmation by GMU headlines:
George Mason University:
Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against
Acutely Infectious Viruses
"Blue skies, smilin' at me
Nothin' but blue skies do I see"